KMT2A and cancer: These “MYC-dependent” cancers include those with activating MYC translocations such as acute myeloid leukemia (AML)15, B-cell acute lymphoblastic leukemia (B-ALL)14, Burkett’s lymphoma (BL)13, mixed-lineage leukemia (MLL)16, and multiple myeloma12, as well as neuroblastoma17, colorectal5,18, breast19, and pancreatic20,21 cancers.